BRANDI HUBBARD: Open Payments
NPI 1164930939 · NORTHPORT, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$454 in 23 payments from 11 companies in 2025. Trend: 2023 $55 · 2024 $233 · 2025 $454
Food & beverage: $454
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $174 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Amgen Inc. | 2 | $34 |
| UCB, Inc. | 1 | $31 |
| Novartis Pharmaceuticals Corporation | 2 | $28 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| PFIZER INC. | 1 | $19 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
Products named: VRAYLAR, BOTOX, REXULTI, UPLIZNA, Briviact, KESIMPTA, Xeomin, Dysport.
Industry payments across AL — which companies pay providers there.
